Scandion Oncology: PANTAX Phase I trial meets primary endpoint - Edison
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Scandion Oncology: PANTAX Phase I trial meets primary endpoint - Edison

{newsItem.title}

Scandion Oncology has announced that the Phase Ib PANTAX trial has concluded and reached its primary endpoint. This study (n=22) evaluated SCO-101, the company’s lead asset, as an add-on therapy for patients with advanced pancreatic cancer (PC). SCO-101, in combination with the chemotherapy agents gemcitabine and nab-paclitaxel, demonstrated a favourable safety and tolerability profile and a maximum tolerated dose (MTD) was established at 200mg for six consecutive days every two weeks. Management has communicated that a more detailed analysis on the full data will be conducted in due course, before deciding the next steps for developing SCO-101 in this indication.

Länk till analysen i sin helhet: https://www.edisoninvestmentresearch.com/research/company/scandion-oncology

Länk till analysen i sin helhet: https://www.edisoninvestmentresearch.com/research/report/scandion-oncology632290/preview

Nyheter om Scandion Oncology

Läses av andra just nu

Om aktien Scandion Oncology

Senaste nytt